Sermorelin acetate (GHRH(1-29)-NH₂) is a synthetic 29-amino-acid peptide corresponding to the amino-terminal segment of endogenous human Growth Hormone-Releasing Hormone (GHRH). As the biologically active fragment of GHRH — the full-length form of which contains 44 amino acids — Sermorelin retains full agonist activity at the GHRH receptor (GHRHR) while providing a more tractable research compound due to its defined sequence and synthesis reproducibility. First approved in the United States under the brand name Geref for diagnostic use in evaluating GH secretory capacity, Sermorelin's receptor pharmacology has been extensively characterized in both cell-based and animal research models.
For laboratory researchers studying the hypothalamic-pituitary-somatotroph axis, Sermorelin represents a well-validated research probe for GHRHR-dependent signaling and a reference compound for evaluating newer GHRH analog modifications.
Biochemical Identity & Structural Properties
| Property | Value |
|---|---|
| Full Name | Sermorelin / GHRH(1-29)-NH₂ / Somatocrinin(1-29) |
| Sequence | First 29 amino acids of human GHRH, C-terminal amide |
| Molecular Weight | ~3,357 g/mol |
| CAS Number | 86168-78-7 |
| Classification | GHRH analog; GHRHR full agonist |
| Target Receptor | GHRHR (Gαs-coupled GPCR) |
| Solubility | Water-soluble; dilute acetic acid may aid dissolution of high-concentration stocks |
| Storage (lyophilized) | −20°C, desiccated, protected from light |
Proposed Mechanisms of Action
GHRHR Binding & cAMP Cascade
Sermorelin's mechanism of action is mediated through high-affinity binding to the GHRH receptor on anterior pituitary somatotroph cells. GHRHR is a class B GPCR coupled to Gαs, and ligand binding activates adenylyl cyclase, elevates intracellular cAMP, and activates protein kinase A (PKA). PKA in turn phosphorylates downstream targets including CREB (cAMP Response Element Binding protein), driving transcriptional programs associated with GH gene expression and somatotroph proliferation. In research settings, cAMP accumulation assays and CREB phosphorylation immunoblots have been used to quantify GHRHR activation by Sermorelin in pituitary-derived cell lines.
GH Pulse Regulation Research
The physiological release of GH from the anterior pituitary is governed by the interplay of hypothalamic GHRH (stimulatory) and somatostatin (inhibitory). Sermorelin's defined pharmacology has made it a reference compound in research studying the temporal dynamics of GH pulses. Studies using perifusion systems with primary pituitary cells or somatotroph-derived cell lines have examined how Sermorelin pulse frequency and amplitude influence GH secretory output and somatotroph responsiveness over time.
Somatotroph Cell Biology
Beyond acute GH secretion, research has examined Sermorelin's effects on somatotroph cell biology — including apparent upregulation of GH gene transcription (via Pit-1/GHF-1 transcription factor pathways), effects on somatotroph cell number in aged animal models, and influence on pituitary GHRHR expression levels. These findings have positioned Sermorelin as a useful research tool for studying pituitary plasticity and somatotroph function across age groups in animal research models.
Summary of Published Research Findings
- Diagnostic pharmacology: Walker (2006) documented Sermorelin's role as a diagnostic research agent for GH secretory capacity evaluation, establishing the pharmacodynamic basis for its research utility in GH axis characterization studies.
- Aged animal models: Research in aged rodent models has examined GHRH analog administration effects on hypothalamic GHRH gene expression, pituitary somatotroph number, and GH pulse amplitude — with Sermorelin serving as a reference GHRH compound in these studies.
- Sleep and GH axis research: Animal research has examined the relationship between GHRH signaling and GH secretion during sleep phases, with Sermorelin used as a research tool to characterize the GHRH contribution to nocturnal GH release patterns.
- Metabolic effects in research models: Studies in GH-deficient animal models have examined the metabolic consequences of restored GH pulsatility via GHRH agonism, documenting effects on body composition, bone mineral density, and insulin sensitivity markers in research settings.
Key Published References
Walker RF. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307–308. PMID: 18046908
Müller EE, Locatelli V, Cocchi D. (1999). Neuroendocrine control of growth hormone secretion. Physiological Reviews, 79(2), 511–607. PMID: 10221989
Corpas E, Harman SM, Blackman MR. (1993). Human growth hormone and human aging. Endocrine Reviews, 14(1), 20–39. PMID: 8491152
Storage & Laboratory Handling
- Lyophilized powder: Store at −20°C in desiccated, light-protected vials. Stable for 24+ months.
- Reconstitution: Sterile water or 0.9% saline. For high-concentration stocks, dilute acetic acid (0.1%) can improve initial dissolution before buffering to physiological pH.
- Working solutions: 2–8°C; use within 14 days. The C-terminal amide of Sermorelin provides additional stability vs. the free acid, but repeated freeze-thaw cycles should still be avoided.
